PUBLISHER: Lucintel | PRODUCT CODE: 1387209
PUBLISHER: Lucintel | PRODUCT CODE: 1387209
Adalimumab Biosimilar Trends and Forecast
The future of the global adalimumab biosimilar market looks promising with opportunities in the hospitals pharmacy and retail pharmacy markets. The global adalimumab biosimilar market is expected to reach an estimated $2.79 billion by 2030 with a CAGR of 21.6% from 2024 to 2030. The major drivers for this market are the growing incidence of arthritis drugs along with rising number of skin disorders.
A more than 150-page report is developed to help in your business decisions.
Adalimumab Biosimilar by Segment
The study includes a forecast for the global adalimumab biosimilar by product, end use, and region.
Adalimumab Biosimilar Market by Product [Shipment Analysis by Value from 2018 to 2030]:
Adalimumab Biosimilar Market by End Use [Shipment Analysis by Value from 2018 to 2030]:
Adalimumab Biosimilar Market by Region [Shipment Analysis by Value from 2018 to 2030]:
List of Adalimumab Biosimilar Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies adalimumab biosimilar companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the adalimumab biosimilar companies profiled in this report include-
Adalimumab Biosimilar Market Insights
Lucintel forecasts that exemptia is expected to witness the highest growth over the forecast period.
Within this market, hospitals pharmacies is expected to remain the largest segment due to the fact that adalimumab biosimilars are used to treat a variety of autoimmune diseases, which are typically managed by specialists in hospital settings.
North America will remain the largest region during the forecast period due to the growing prevalence of rheumatoid arthritis along with the rise in the geriatric population.
Features of the Global Adalimumab Biosimilar Market
Market Size Estimates: Adalimumab biosimilar market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Adalimumab biosimilar market size by product, end use, and region in terms of value ($B).
Regional Analysis: Adalimumab biosimilar market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different products, end uses, and regions for the adalimumab biosimilar market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the adalimumab biosimilar market.
Analysis of competitive intensity of the industry based on Porter's Five Forces model.
FAQ
Q1. What is the adalimumab biosimilar market size?
Answer: The global adalimumab biosimilar market is expected to reach an estimated $2.79 billion by 2030.
Q2. What is the growth forecast for adalimumab biosimilar market?
Answer: The global adalimumab biosimilar market is expected to grow with a CAGR of 21.6% from 2024 to 2030.
Q3. What are the major drivers influencing the growth of the adalimumab biosimilar market?
Answer: The major drivers for this market are the growing incidence of arthritis drugs along with rising number of skin disorders.
Q4. What are the major segments for adalimumab biosimilar market?
Answer: The future of the adalimumab biosimilar market looks promising with opportunities in the hospitals pharmacy and retail pharmacy markets.
Q5. Who are the key adalimumab biosimilar market companies?
Answer: Some of the key adalimumab biosimilar companies are as follows:
Q6. Which adalimumab biosimilar market segment will be the largest in future?
Answer: Lucintel forecasts that exemptia is expected to witness the highest growth over the forecast period.
Q7. In adalimumab biosimilar market, which region is expected to be the largest in next 5 years?
Answer: North America will remain the largest region during the forecast period due to the growing prevalence of rheumatoid arthritis along with the rise in the geriatric population.
Q.8 Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.